INTRODUCTION AND OBJECTIVES: Gold standard treatment for muscle invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant chemotherapy (NAC). However, the survival benefit of NAC in unselected patients is considered modest (5-15%). Recently genomic studies identified intrinsic basal, p53-like, and luminal molecular subtypes of MIBC which identify the genetic heterogeneity of bladder cancer. We hypothesized that tumor intrinsic subtype at the time of staging transurethral resection (TURBT) could be associated with clinical benefit from NAC.
INTRODUCTION AND OBJECTIVES: Gold standard treatment for muscle invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant chemotherapy (NAC). However, the survival benefit of NAC in unselected patients is considered modest (5-15%). Recently genomic studies identified intrinsic basal, p53-like, and luminal molecular subtypes of MIBC which identify the genetic heterogeneity of bladder cancer. We hypothesized that tumor intrinsic subtype at the time of staging transurethral resection (TURBT) could be associated with clinical benefit from NAC.
METHODS: We identified patients with MIBC who underwent RC with or without NAC between 2000 and 2010 at three different institutions. Whole-genome analysis was performed on TURBT specimens and were classified into basal, luminal or p53-like subtypes. Primary outcome is overall survival (OS). Secondary outcome is response is tumor downstaging (<pT2 at RC).
RESULTS: 273 TURBT specimens were analyzed. There were no significant differences in the subtypes between age, sex and stage (p<0.05). 87 (32%) were basal, 95 (35%) were p53-like, and 91 (33%) were luminal. 127 (46%) did not get NAC, and 146 (54%) received NAC. Downstaging occurred in 69 of 273 patients (26%), 2% (2/127) did not receive NAC and 47% (69/146) received NAC (p<0.001). Of patients that received NAC, 51% (25/49) of basal, 33% (16/48) p53-like, and 57% (28/49) of luminal tumors were downstaged (p¼0.033). Median OS for patients who did not receive NAC was 33 mo. vs. 102 mo. for those who did (p<0.0001). OS was improved for patients who did vs. those who did not get NAC in basal subtypes (17 mo. vs. 271 mo., p<0.001). However, there was no significant difference in OS for p53-like (58 mo. vs. 70 mo., p¼0.3137), and for luminal (43 mo. vs. 85 mo., p¼0.0629) . For patients that did get NAC, patients with basal tumors had a significant increase in OS over to the other subtypes (p¼0.0239) ( Figure 1 ). CONCLUSIONS: Basal tumors in the absence of NAC are high risk, but they have a favorable response to NAC which results in an increased OS. Luminal tumors have a favorable downstage rate at RC, but this does not translate into increased OS. P53-like tumors have a poor prognosis regardless of use of NAC. We demonstrate that the intrinsic molecular subtypes of MIBC identified at TURBT have variable response to NAC with significant implications on OS.
Source of Funding: National Cancer Institute SPORE & VF Foundation

PD62-04 SAFETY AND EFFICACY GEMCITABINE-CISPLATIN SPLIT DOSE AS A NEOADUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
Mohamed Abdelhafez*, Assuit, Egypt; Michael Williams, Norfolk, VA INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy (NAC) (Cisplatin based) and radical cystectomy are currently level 1 recommendation for muscle invasive bladder cancer. Gemcitabine-Cisplatin regimens are gaining popularity as (NAC). Only few data at present about splitting the doses in order to decrease toxicity, used with patients with lower renal function and achieve more patient compliance. The objective of this study is to study the effectiveness and safety of split dose Gemcitabine and Cisplatine as a NAC for muscle invasive bladder cancer.
METHODS: All consecutive patients from 2004 to 2015 that received Gemcitabine and Cisplatine split doses and followed by open radical cystectomy for T2-T4 bladder cancer were included in the study. All patients administered 1,000 mg/m2 of gemcitabine and 35 mg/m2 of Cisplatin given on days 1 and 8 of a 21 days cycle for 4 cycles. Preoperative patients' clinical parameters, need for dose reduction, number of cycles complications of NAC and pathologic response were recorded. Patients with unavailable follow up data were excluded from the study. Fisher exact test was used for univariate analysis to detect preoperative factors affecting pathologic response.
RESULTS: Eighty two patients met the inclusion criteria. Only 10 patents (12 %) couldn't complete 4 cycles because of complications. 38 patients (46%) were down staged (pT 1) and 32 achieved complete response (pT0). Median follow up time was 29 months. Univariate analysis for detecting factors affect pathologic response showed no significant effect of Gender (p¼0.742), race (p¼0.783), Age (p¼0.377), BMI (p¼0.821), T stage (0.982), N stage (0.615), presence of Cis (0.096), squamous differentiation (p¼0.229) and presence of lymphovasular invasion (p¼0.749).
CONCLUSIONS: Splitting the dose of Gemcitabine and Cisplatine as a NAC for muscle invasive bladder cancer has a good pathologic response with high safety profile. Patients with different preoperative characters can get benefit from this regimen. evaluated (RECIST criteria): CR was observed in 2 pts (6%), PR in 18 (60%); PD in 1 (3%) and SD in 9 (30%) regarding primary bladder tumor. In 12 pts with enlarged lymph-nodes, the response to NGC was CR in 1, PR in 10 and SD in 1. Patients receiving neoadjuvant GC had a greater chance of achieving a pathologically lower stage compared to the untreated population: organ-confined cancer in 53,3% (16/30) vs. 33% (p < 0.001). Lymph-node metastasis resulted in 25% patients after GC (n¼10) vs 45.5% of untreated patients (n¼20; p < 0.001).
Source of
Considering patients resulted CR and PR after NGC (n¼20), 70% had down-staging on pathologic report after RC. Complication rates were higher in NGC group (4 thromboembolisms; 2 sepsis; 12 hematologic complications); all complications were not related to surgery. Pathological TRG after NGC was not correlated to clinical regression grade. The OS (mean follow-up 30 months) of patients who received NGC resulted of 66.6% compared with 56% of patients undergoing cystectomy alone (p<0,001). Fifty percent of patients in NGC group were alive without cancer vs 40,1% in cystectomy alone group (p<0,001). CONCLUSIONS: Neoadjuvant chemotherapy for muscle-invasive bladder cancer increases the rate of down-staging and cancer specific survival. NGC is associated with an increased risk of complications that may be prevented using tailored strategies. Pathological regression grades after NGC are not correlated to RECIST criteria based on CT.
Source of Funding: none
PD62-06 NEOADJUVANT CHEMOTHERAPY FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED OR EARLY NODAL DISEASE: ARE WE DOING ENOUGH?
Andres Correa*, Elizabeth Handorf, Benjamin Ristau, Haifler Haifler, Shreyas Joshi, Robert Uzzo, Rosalia Viterbo, Richard Greenberg, David Chen, Alexander Kutikov, Daniel Geynisman, Marc Smaldone, Philadelpahia, PA INTRODUCTION AND OBJECTIVES: The administration of neoadjuvant chemotherapy (NAC) for patients with muscle invasive urothelial carcinoma improves overall survival and is a category 1 NCCN recommendation. Recent reports have shown that the survival benefit may be greater in patients with locally advance disease and nodal involvement. Here we aim to assess the NAC administration trends in patients with locally advanced and low stage nodal disease using a large national tumor registry.
METHODS: Patients treated for muscle invasive urothelial carcinoma were selected from the National Cancer Data Base. Patients with clinical stage T2-T4 and low stage nodal disease (N0-N2), treated between 2004 and 2014, where included in the study. Patients who underwent chemotherapy as the only treatment where excluded from the analysis. A multivariate analysis was constructed to identify factors that affected administration of NAC. Covariates included in the model were clinical stage, age, race, sex, insurance status, income, Charlson comorbidity index, pathological stage, demographic location, facility location, and diagnosis year.
RESULTS: A total of 19,299 patients met inclusion criteria for the study. NAC utilization increased over the study period with 35.6% of patients receiving NAC in 2014 compared to 10.1% in 2004. Decreasing NAC utilization was noted with increasing age (< 65 years: 28.0%; 65-74 years: 23.9%; 75 years: 12.3%, p<0.001). On multivariate analysis age, clinical stage and patient age were found to be significantly associated with administration of NAC. Increasing clinical stage and early nodal disease was found to be associated with an increase in the administration of NAC, using cT2N0 as a reference, the likelihood of NAC administration of T3N0 and T4N0 and Tany/N1-2 was 1.31 (95% CI 1.14 to 1.50) and 1.63 (95% CI 1.43 and 1.87) respectively (p< 0.001, both). Increasing age was associated with a decrease in the use of NAC, using <65 years as a reference, the likelihood of NAC administration for patients 65-74 years and 75 years was .89 (95% 0.82 to 0.91) and 0.39 (95% CI 0.34 to 0.44), respectively (p¼0.32 and p< 0.001). On interaction analysis between age and clinical stage, the likelihood of receiving NAC still increased with increasing clinical stage in patients < 65 to 74 years old but this effect was non-existent in patients 75 years or older.
CONCLUSIONS: Although the administration of NAC has increased over the last 10 years, the use of NAC in septa and octogenarians remains low; even, in those presenting with advance stage and early nodal disease. with transurethral resection, followed by chemotherapy and radiation for muscle invasive urothelial carcinoma (UC) is typically reserved for patients deemed unfit for radical cystectomy (RC). Recently, some studies have demonstrated reasonable oncologic outcomes after TMT for select patients with muscle invasive UC. We assessed practice patterns for TMT in patients with muscle invasive UC using data from the National Cancer Database (NCDB).
Source of
METHODS: We identified patients with muscle invasive UC of the bladder treated with either RC or TMT between 2004 and 2013. TMT was defined by patients who had transurethral resection plus chemotherapy and radiation therapy within 90 days. Trends in utilization of TMT over time were measured. We compared socioeconomic and clinical variables including age, race, distance from residence to treatment center, urban vs rural residence, median county income, facility type and volume, Charlson comorbidity score (CCS), tumor size and grade, and clinical nodal status between patients receiving RC and TMT and identified predictive factors for receipt of TMT with logistic regression modeling.
RESULTS: Using the NCDB, we identified 18,084 patients that underwent RC (15, 722) or TMT (2,362) for cT2 UC of the bladder. TMT patients were older (median 76 vs 68 years), had higher CCS, and higher rates of clinical node positive disease (for all comparisons, p < 0.001). Tumor size was similar between groups. On multivariable analysis, significant predictors of TMT included increasing age (OR ¼ 4.48 [4.05 e 4.96]), rural residence (OR ¼ 1.27 [1.11 e 1.45]), and facility type (those in an integrated network cancer program were 1.44 times as likely to undergo bladder sparing as those treated at community cancer centers [1.11-1.88]). Negative predictors for TMT were treatment at an academic center (OR ¼ 0.59 [0.48 e 0.73]), treatment at a high volume center (OR ¼ 0.35 [0.29 e 0.43]), and longer distance of residence from treatment center (OR ¼ 0.30 [0.29 e 0.37]). The proportion of patients receiving TMT decreased over the study period.
CONCLUSIONS: Older patients who live in rural areas were more likely to undergo TMT. Treatment at high volume, academic centers and distant residence from treatment center were all negative predictors for receipt of TMT. Further analyses of these two groups is necessary to determine whether these patterns of treatment impact survival of patients with muscle invasive UC.
Source of Funding: None.
PD62-08 CHANGES IN LEAN MUSCLE MASS ASSOCIATED WITH NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Kalen Rimar*, Alexander Glaser, Edward Schaeffer, Joshua Meeks, Shilajit Kundu, Sarah Psutka, Chicago, IL INTRODUCTION AND OBJECTIVES: Baseline sarcopenia is independently associated with increased mortality after cystectomy for muscle-invasive urothelial carcinoma (MIUC). Cytotoxic chemotherapy is associated with variable changes in lean muscle mass in other
